Condition: Phenylketonuria · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
This study is a Phase I single ascending dose clinical trial in which healthy adult volunteers were administered single oral doses of GenSci144 tablets at different levels. It was conducted using a randomized, double-blind, placebo-controlled design, primarily to evaluate the drug's safety and tolerability, while also exploring its pharmacokinetic and pharmacodynamic characteristics in the body, providing a basis for subsequent clinical use in the treatment of phenylketonuria.
This description comes directly from the study's public registry record.
Wei Zhao · +86 15131190710 · zhao4wei2@hotmail.com
Yanlin Chen · +86 18621909391 · chenyanlin01@genscigroup.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital). | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07685210